Patents for protein biomarker Discovery
Peakadilly receives multiple patents for breakthrough Protein
biomarker discovery and identification technologies
The patent offices of the United States of America and Canada have
granted patents for Peakadilly's core technology, COFRADIC®.
COFRADIC® allows the identification and quantification of proteins
in any biological sample and represents the most important component
of the company's MASStermind® biomarker discovery engine. Peakadilly
has already received patents for the technology in Europe.
Peakadilly's proprietary proteomics technologies allow fast,
automated and highly flexible and sensitive qualitative and
quantitative proteomics without using gels and without the use of an
affinity tag. Together with a novel serum depletion technology and
state-of-the art mass spectrometry, Peakadilly's MASStermind®
platform allows to analyse huge sets of proteins and
posttranslational modified proteins in clinical samples like blood
or sputum, offering unrivalled sensitivities and high content data
unseen with genomics & transcriptomics. Using software tools
developed in-house, the quantitative comparison of hundreds of
samples is possible, making the technology suited for biomarker
discovery within clinical trials. In collaboration with a big pharma
company, the technology is currently being applied to distinguish
responders from non-responders in a specific therapeutic regimen.

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech